title: Early and intermediate outcomes of left main coronary intervention.
abstract: OBJECTIVE
  We examined the immediate and long-term outcomes after stenting of all comers for left main coronary artery (LMCA) stenoses.
  
  
  BACKGROUND
  Left main coronary artery disease is regarded as an absolute contraindication for coronary angioplasty. Recently, several reports on protected or unprotected LMCA stenting, or both, suggested the possibility of percutaneous intervention for this prohibited area.
  
  
  METHODS
  Eighty-one consecutive patients with LMCA stenoses were treated with stents. The post-stent antithrombotic regimens were aspirin and clopidogrel. The major adverse cardiac events (MACE) including death, Q-wave myocardial infarction, or repeat target lesion revascularization were followed. Patients were followed very closely and all attended office visit at 12 months.
  
  
  RESULTS
  The procedural success rate was 86.4%, with no episodes of acute thrombosis. Follow-up angiography was performed in 30 of 65 eligible patients (46.2%). Angiographic restenosis occurred in eight patients (9.9%). Cumulative death occurred in 16 patients (19.7%). MACE at 30 day and 12-month was 12.3% and 33.3% respectively. From multivariate analysis, dialysis (HR =3.22, p = 0.048), urgent PCI (HR =2.39, p = 0.036), post-procedure TIMI flow < 3 (HR =25.99, p = 0.001) and final kissing balloon inflation (HR = 0.30, p = 0.04) were independent predictors of MACE at 12-month. There was one definite late stent thrombosis (1.2%).
  
  
  CONCLUSIONS
  Stenting of LMCA stenosis may be a safe and effective alternative to CABG in carefully selected patients. Further studies in larger patient populations are needed to assess late outcome.
authors.affiliation: Division of Cardiology, Department of Medicine, Faculty of Medicine, Siriraj Hospital and Her Majesty Cardiac Center, Mahidol University, Bangkok, Thailand.
authors.forename: Damras
authors.initials: D
authors.lastname: Tresukosol
authors.forename: Supadet
authors.initials: S
authors.lastname: Sudjaritruk
authors.forename: Suwatchai
authors.initials: S
authors.lastname: Pornratanarangsi
authors.forename: Chunhakasem
authors.initials: C
authors.lastname: Chotinaiwattarakul
authors.forename: Rewat
authors.initials: R
authors.lastname: Phankingthongkum
authors.forename: Wiwun
authors.initials: W
authors.lastname: Tungsubutra
authors.forename: Nattawut
authors.initials: N
authors.lastname: Wongpraparat
authors.forename: Tippayawan
authors.initials: T
authors.lastname: Lerdwilai
authors.forename: Pradit
authors.initials: P
authors.lastname: Panchavinnin
mesh_terms: D000368:Aged; D015906:Angioplasty, Balloon, Coronary / Q000379:methods*; D001241:Aspirin / Q000008:administration & dosage; D000077144:Clopidogrel; D017023:Coronary Angiography; D003327:Coronary Disease / Q000000981:diagnostic imaging / Q000453:epidemiology / Q000628:therapy*; D003331:Coronary Vessels / Q000000981:diagnostic imaging*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage; D012189:Retrospective Studies; D015607:Stents; D013534:Survival; D013988:Ticlopidine / Q000008:administration & dosage / Q000031:analogs & derivatives; D013997:Time Factors; D016896:Treatment Outcome; D014463:Ultrasonography; D016277:Ventricular Function, Left
chemical_list: D010975:Platelet Aggregation Inhibitors; D000077144:Clopidogrel; D013988:Ticlopidine; D001241:Aspirin